Targeting Pharmacotherapy to Effectively Manage Eosinophilic Esophagitis

To participate in this activity, please:

Two leading specialists in eosinophilic esophagitis (EoE) explore the increasing disease burden of this underrecognized cause of esophageal dysfunction that affects all age groups worldwide. A type-2 inflammatory condition, EoE is frequently characterized by allergic comorbidity but can also be misdiagnosed as the more common condition of gastroesophageal reflux disease. New and emerging treatments promise to improve outcomes for people with EoE. Drs. Mirna Chehade and Ikuo Hirano share best practices, as well as their own insights and clinical pearls based on their research and clinical practice with children and adults with EoE. This can lead to more expedient diagnosis, better adherence to treatment, and reduced disease burden. This interactive, case-based activity is designed for practicing clinicians. The faculty include lessons learned, quality-of-life considerations, and the near-term outlook for management of people with EoE.  

Course Credit:

1.5 AMA PRA Category 1 CreditsTM
1.5 ANCC Contact Hours
1.5 CA-BRN Contact Hours
0.75 Pharmacology Hours


Opens: 2023-03-28
Closes: 2024-03-28

Target Audience:

This activity is intended for gastroenterologists, allergists/immunologists, internists, pediatric subspecialists, physician associates, nurse practitioners, and other clinicians who manage individuals with EoE.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

    Presenting Faculty

  • Mirna Chehade, MD, MPH

    Professor of Pediatrics and Medicine
    Founding Director, Mount Sinai Center for Eosinophilic Disorders
    Icahn School of Medicine at Mount Sinai
    New York, New York

  • Ikuo Hirano, MD

    Professor of Medicine
    Division of Gastroenterology and Hepatology
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois